Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1839.87% is 26% below its 5-year average of -1456.69%, near the high end of its 5-year range (-8260.32%–-571.02%).
19.16% above its 12-month average of -2276.07%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2073.17%.
EBITDA MARGIN
-1839.87%
EBITDA MARGIN AVG TTM
-2276.07%
EBITDA MARGIN AVG 3Y
-1756.46%
EBITDA MARGIN AVG 5Y
-1456.69%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+19.16%
CURRENT VS 3Y AVG
-4.75%
CURRENT VS 5Y AVG
-26.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Longeveron Inc.
Market Cap
$7.27M
EBITDA Margin
-1839.87%
TTM Avg
-2276.07%
3Y Avg
-1756.46%
5Y Avg
-1456.69%
Market Cap
$7.16M
EBITDA Margin
-2068.24%
TTM Avg
-1510.83%
3Y Avg
-1474.78%
5Y Avg
-1474.78%
Market Cap
$6.98M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.23M
EBITDA Margin
3.56%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$7.25M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$6.99M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$6.75M
EBITDA Margin
-4847.72%
TTM Avg
-2918.14%
3Y Avg
-1630.06%
5Y Avg
-1069.46%
Market Cap
$6.66M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.27M | -1839.87% | -2276.07% | -1756.46% | -1456.69% |
| KALA BIO, Inc. (KALA)vs › | $7.16M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | 3.56% | 3.56% | 3.56% | 3.56% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -0.29% | -74.83% | -125.41% | -344.12% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | -430.70% | -678.73% | -962.21% | -5357.45% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.75M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
| Aclarion, Inc. (ACON)vs › | $6.66M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.50M | -10.17% | -10.02% | -12.29% | -11.98% |
Gross Margin
69.8%
EBITDA Margin
-1839.9%
Operating Margin
-1942.2%
Net Margin
-1977.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2073.17% |
| 2026-03-31 | -1136.43% |
| 2025-12-31 | -1403.01% |
| 2025-09-30 | -5143.07% |
| 2025-06-30 | -1624.68% |
| 2025-03-31 | -1249.34% |
| 2024-12-31 | -669.82% |
| 2024-09-30 | -571.02% |
| 2024-06-30 | -698.93% |
| 2024-03-31 | -700.36% |
| 2023-12-31 | -8260.32% |
| 2023-09-30 | -3286.00% |
| 2023-06-30 | -2521.66% |
| 2023-03-31 | -1881.51% |
| 2022-12-31 | -4136.36% |
| 2022-09-30 | -1866.79% |
| 2022-06-30 | -856.65% |
| 2022-03-31 | -866.49% |
| 2021-12-31 | -1818.18% |
| 2021-09-30 | -2012.50% |
| 2021-06-30 | -983.84% |
| 2021-03-31 | -867.82% |
| 2020-12-31 | -100.63% |
| 2020-09-30 | -40.75% |
| 2020-06-30 | -117.47% |
| 2020-03-31 | -1.05% |
| 2019-12-31 | -15.15% |
